Format

Send to

Choose Destination
Circulation. 2018 Mar 20;137(12):1218-1220. doi: 10.1161/CIRCULATIONAHA.117.030117.

Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist.

Author information

1
Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, United Kingdom (M.A.B.) angelyn.bethel@dtu.ox.ac.uk.
2
British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.J.V.M.).

KEYWORDS:

SGLT-2 inhibitor; canagliflozin; cardiovascular diseases; diabetes mellitus; empagliflozin; mortality; myocardial infarction

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center